Cookies help us deliver our services. By using our services, you agree to our use of cookies. More information

Difference between revisions of "Warne 2015 J Biol Chem"

From Bioblast
Line 1: Line 1:
{{Publication
{{Publication
|title=Warne J, Pryce G, Hill J, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D, Selwood D (2015) Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis. J Biol Chem [Epub ahead of print].  
|title=Warne J, Pryce G, Hill J, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D, Selwood D (2015) Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis. J Biol Chem [Epub ahead of print].
|info=[http://www.ncbi.nlm.nih.gov/pubmed/26679998 PMID: 26679998 Open Access]
|info=[http://www.ncbi.nlm.nih.gov/pubmed/26679998 PMID: 26679998 Open Access]
|authors=Warne J, Pryce G, Hill J, Shi X, Lenneraas F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D*, Selwood D
|authors=Warne J, Pryce G, Hill J, Shi X, Lenneraas F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D*, Selwood D
Line 6: Line 6:
|journal=J Biol Chem
|journal=J Biol Chem
|abstract=The mitochondrial permeability transition pore (PT pore) is a recognised drug target for neurodegenerative conditions such as multiple sclerosis (MS) and for ischaemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, ppif) is a positive regulator of the pore and genetic downregulation or knockout improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off target effects, immune-suppression and toxicity. We therefore designed and synthesised a new mitochondrially-targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine (CsA). X-ray analysis was used to validate the design concept and biological evaluation revealed selective cellular inhibition of CypD and the PT pore with reduced cellular toxicity compared to CsA. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis (MS), JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for ''in vivo'' use.
|abstract=The mitochondrial permeability transition pore (PT pore) is a recognised drug target for neurodegenerative conditions such as multiple sclerosis (MS) and for ischaemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, ppif) is a positive regulator of the pore and genetic downregulation or knockout improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off target effects, immune-suppression and toxicity. We therefore designed and synthesised a new mitochondrially-targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine (CsA). X-ray analysis was used to validate the design concept and biological evaluation revealed selective cellular inhibition of CypD and the PT pore with reduced cellular toxicity compared to CsA. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis (MS), JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for ''in vivo'' use.
|keywords=EAE, X-ray crystallography, Cyclophilin D, Cyclosporin, Mitochondrial permeability transition (MPT), Mitochondrial targeting, Multiple sclerosis, Neurodegeneration, Neurodegenerative disease
|keywords=EAE, X-ray crystallography, Cyclophilin D, Cyclosporin, Mitochondrial permeability transition (MPT), Mitochondrial targeting, Multiple sclerosis, Neurodegeneration, Neurodegenerative disease, Calcium retention capacity
|mipnetlab=UK London Duchen MR
|mipnetlab=UK London Duchen MR
}}
}}
Line 13: Line 13:
|organism=Mouse
|organism=Mouse
|tissues=Liver
|tissues=Liver
|preparations=Isolated mitochondria
|injuries=Permeability transition
|diseases=Neurodegenerative
|diseases=Neurodegenerative
|topics=Inhibitor
|topics=Inhibitor
Line 18: Line 20:
|substratestates=CI, ROX
|substratestates=CI, ROX
|instruments=Oxygraph-2k
|instruments=Oxygraph-2k
|additional=Labels, [Epub ahead of print], 2016-01
|additional=[Epub ahead of print], 2016-01
}}
}}
== Clarification ==
== Clarification ==
*Baker D refers to David Baker of Queen Mary University of London and not [[Baker D|Daniel Baker]] of the University of Auckland
*Baker D refers to David Baker of Queen Mary University of London and not [[Baker D|Daniel Baker]] of the University of Auckland

Revision as of 13:31, 8 March 2016

Publications in the MiPMap
Warne J, Pryce G, Hill J, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D, Selwood D (2015) Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis. J Biol Chem [Epub ahead of print].

» PMID: 26679998 Open Access

Warne J, Pryce G, Hill J, Shi X, Lenneraas F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker A, Duchen MR, Szabadkai G, Baker D*, Selwood D (2015) J Biol Chem

Abstract: The mitochondrial permeability transition pore (PT pore) is a recognised drug target for neurodegenerative conditions such as multiple sclerosis (MS) and for ischaemia-reperfusion injury in the brain and heart. The peptidylprolyl isomerase, cyclophilin D (CypD, ppif) is a positive regulator of the pore and genetic downregulation or knockout improves outcomes in disease models. Current inhibitors of peptidylprolyl isomerases show no selectivity between the tightly conserved cyclophilin paralogs and exhibit significant off target effects, immune-suppression and toxicity. We therefore designed and synthesised a new mitochondrially-targeted CypD inhibitor, JW47, using a quinolinium cation tethered to cyclosporine (CsA). X-ray analysis was used to validate the design concept and biological evaluation revealed selective cellular inhibition of CypD and the PT pore with reduced cellular toxicity compared to CsA. In an experimental autoimmune encephalomyelitis disease model of neurodegeneration in multiple sclerosis (MS), JW47 demonstrated significant protection of axons and improved motor assessments with minimal immunosuppression. These findings suggest that selective CypD inhibition may represent a viable therapeutic strategy for MS and identify quinolinium as a mitochondrial targeting group for in vivo use. Keywords: EAE, X-ray crystallography, Cyclophilin D, Cyclosporin, Mitochondrial permeability transition (MPT), Mitochondrial targeting, Multiple sclerosis, Neurodegeneration, Neurodegenerative disease, Calcium retention capacity

O2k-Network Lab: UK London Duchen MR


Labels: MiParea: Respiration, mt-Membrane  Pathology: Neurodegenerative  Stress:Permeability transition  Organism: Mouse  Tissue;cell: Liver  Preparation: Isolated mitochondria 

Regulation: Inhibitor  Coupling state: LEAK, OXPHOS, ETS"ETS" is not in the list (LEAK, ROUTINE, OXPHOS, ET) of allowed values for the "Coupling states" property. 

HRR: Oxygraph-2k 

[Epub ahead of print], 2016-01 

Clarification

  • Baker D refers to David Baker of Queen Mary University of London and not Daniel Baker of the University of Auckland